Description
Ranibizumab, marketed under the brand name LUCENTIS, It is an prescription medication that has been approved ranibizumab (Lucentis) injection on June 30, 2006. The European Union approved it in January 2007.
What is Lucentis (Ranibizumab) ?
LUCENTIS® is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD).
Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the “wet” type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
How to order approved “Lucentis (Ranibizumab) for Injection” Medicine?
LUCENTIS (Ranibizumab) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing LUCENTIS and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
